Choose a folder
DISCOVER presentation success at ADA 2018
The DISCOVER team gave four fantastic poster presentations of 1-year global data at ADA 2018, 22–26 June in Orlando, FL, USA.
DISCOVER had a great presence this year at ADA, with four posters and one moderated poster session! The DISCOVER Scientific Committee were very excited to share this bounty of 1-year data with the attendees of this major international congress. Please keep reading for more details from each poster!
Professor Kamlesh Khunti presented a poster titled Individualized HbA1c targets in people with type 2 diabetes initiating second-line therapy: the global DISCOVER study (1629-P). Of the 14 169 patients enrolled in DISCOVER, 7225 (51.0%) had glycated haemoglobin (HbA1c) data at baseline and 12 months. Of these, 5070 (70.2%) had been set an individualized HbA1c target by their physician, which was either 6.5% or 7.0%. Twelve months after initiating second-line therapy, 34.4% of patients had met their individualized HbA1c targets. Overall, proportions of patients with routinely measured HbA1c and with an individualized HbA1c target were low.
Professor Bernard Charbonnel presented a poster titled Change over 12 months in HbA1c, fasting plasma glucose and weight among patients with type 2 diabetes in 37 countries: DISCOVER (1615-P). This poster was also included in a moderated discussion titled Type 2 diabetes – risk factors and complications on Saturday 23 June. The analysis showed substantially decreased HbA1c and fasting plasma glucose (FPG) levels after 1 year in all treatment categories. Changes in weight were moderate. Mean weight increased in patients receiving a sulfonylurea or insulin, and decreased in those receiving a dipeptidyl peptidase-4 inhibitor on its own or with metformin.
Two posters were led by Dr Mikhail Kosiborod. The first poster, Temporal trends in the use of sodium-glucose co-transporter-2 inhibitors: the global DISCOVER study (1141-P), examined trends in the use of sodium-glucose co-transporter-2 inhibitors (SGLT-2is). The EMPA-REG OUTCOME trial (NCT01131676) results suggest that SGLT-2i therapy reduces the risk of cardiovascular events in patients with type 2 diabetes who have established cardiovascular disease. The proportion of DISCOVER patients prescribed an SGLT-2i as second- or later-line therapy was low (9.7%) and varied across regions (lowest in Africa, 0.0%; highest in the Americas, 18.3%). The use of SGLT-2is increased slightly after publication of the EMPA-REG OUTCOME results, but the clinical decision to prescribe an SGLT-2i does not appear to be driven by the presence of macrovascular complications; proportions of patients with such complications were similar in those receiving an SGLT-2i and in those receiving other agents.
The second poster led by Dr Kosiborod, Vascular events in patients with type 2 diabetes in the year following initiation of second-line therapy: the DISCOVER study (1562-P), assessed the occurrence of microvascular and macrovascular complications during the first year of follow-up. Overall, incident microvascular and macrovascular complications were reported in 6.6% and 4.7% of patients, respectively, with substantial variation across regions (across region range: microvascular, 1.0–14.8%; macrovascular, 2.2–7.3% ). Having a history of vascular complications at baseline was predictive for developing new complications during the first year of follow-up. These findings highlight the opportunity for early aggressive risk factor modification in patients with type 2 diabetes.
The DISCOVER team would like to extend their heartfelt thanks to the investigators who collected data for these presentations and continue to work hard for the success of the DISCOVER study. Lastly, please keep visiting the DISCOVER website for more news about upcoming global and local presentations during the rest of 2018. There are a lot of exciting things in development, so stay tuned!